Phase II Randomized, Double-blind, Placebo-controlled Study of Whole-brain Irradiation with Concomitant Chloroquine for Brain Metastases

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2013 Sep 10

PMID 24010771

Citations 73

Authors

Luis L Rojas-Puentes

Marcelino Gonzalez-Pinedo

Alejando Crismatt

Alette Ortega-Gomez

Carlos Gamboa-Vignolle

Rodrigo Nunez-Gomez

Yusmiren Dorantes-Gallareta

Claudia Arce-Salinas

Oscar Arrieta

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Chloroquine (CLQ), an antimalarial drug, has a lysosomotropic effect associated with increased radiationsensibility, which is mediated by the leakage of hydrolytic enzymes, increased apoptosis, autophagy and increased oxidative stress in vitro. In this phase II study, we evaluated the efficacy and safety of radiosensibilization using CLQ concomitant with 30 Gray (Gy) of whole-brain irradiation (WBI) to treat patients with brain metastases (BM) from solid tumors.

Methods: Seventy-three eligible patients were randomized. Thirty-nine patients received WBI (30 Gy in 10 fractions over 2 weeks) concomitant with 150 mg of CLQ for 4 weeks (the CLQ arm). Thirty-four patients received the same schedule of WBI concomitant with a placebo for 4 weeks (the control arm). All the patients were evaluated for quality of life (QoL) using the EORTC Quality of Life (QoL) Questionnaire (EORTC QLQ-C30) (Mexican version) before beginning radiotherapy and one month later.

Results: The overall response rate (ORR) was 54% for the CLQ arm and 55% for the control arm (p=0.92). The progression-free survival of brain metastases (BMPFS) rates at one year were 83.9% (95% CI 69.4-98.4) for the CLQ arm and 55.1% (95% CI 33.6-77.6) for the control arm. Treatment with CLQ was independently associated with increased BMPFS (RR 0.31,95% CI [0.1-0.9], p=0.046).The only factor that was independently associated with increased overall survival (OS) was the presence of< 4 brain metastases (RR 1.9, 95% CI [1.12-3.3], p=0.017). WBI was associated with improvements in cognitive and emotional function but also with worsened nausea in both patients groups. No differences in QoL or toxicity were found between the study arms.

Conclusion: Treatment with CLQ plus WBI improved the control of BM (compared with the control arm) with no increase in toxicity; however, CLQ did not improve the RR or OS. A phase III clinical trial is warranted to confirm these findings.

Citing Articles

Repurposing radiosensitising medicines for radiotherapy: an overview.

Low J, Rodriguez-Berriguete G, Higgins G BMJ Oncol. 2025; 3(1):e000192.

PMID: 39886153 PMC: 11235008. DOI: 10.1136/bmjonc-2023-000192.

LOC730101 improves ovarian cancer drug sensitivity by inhibiting autophagy-mediated DNA damage repair via BECN1.

Zhong Y, Shuai Y, Yang J, Zhang M, He T, Zheng L Cell Death Dis. 2024; 15(12):893.

PMID: 39695078 PMC: 11655529. DOI: 10.1038/s41419-024-07278-1.

SLC34A2 promotes cell proliferation by activating STX17-mediated autophagy in esophageal squamous cell carcinoma.

Xu Y, Duan S, Ye W, Zheng Z, Zhang J, Gao Y Thorac Cancer. 2024; 15(17):1369-1384.

PMID: 38720472 PMC: 11168907. DOI: 10.1111/1759-7714.15314.

Evolution of the Management of Brain Metastases: A Bibliometric Analysis.

Burney I, Aal Hamad A, Hashmi S, Ahmad N, Pervez N Cancers (Basel). 2023; 15(23).

PMID: 38067273 PMC: 10705608. DOI: 10.3390/cancers15235570.

Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.

Garcia M, Tsang K, Lohit S, Deng J, Schneider T, Matos Silva J Ann Pharmacother. 2023; 58(7):742-755.

PMID: 37881891 PMC: 11151715. DOI: 10.1177/10600280231204969.

References

Maclean K, Dorsey F, Cleveland J, Kastan M . Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest. 2007; 118(1):79-88. PMC: 2148253. DOI: 10.1172/JCI33700. View

Sotelo J, Briceno E, Lopez-Gonzalez M . Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006; 144(5):337-43. DOI: 10.7326/0003-4819-144-5-200603070-00008. View

Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R . A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322(8):494-500. DOI: 10.1056/NEJM199002223220802. View

Mehta M, Paleologos N, Mikkelsen T, Robinson P, Ammirati M, Andrews D . The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):71-83. PMC: 2808518. DOI: 10.1007/s11060-009-0062-7. View

Carew J, Medina E, Esquivel 2nd J, Mahalingam D, Swords R, Kelly K . Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2009; 14(10):2448-59. PMC: 2891399. DOI: 10.1111/j.1582-4934.2009.00832.x. View

Toler S, Noe D, Sharma A . Selective enhancement of cellular oxidative stress by chloroquine: implications for the treatment of glioblastoma multiforme. Neurosurg Focus. 2007; 21(6):E10. DOI: 10.3171/foc.2006.21.6.1. View

Langer C, Mehta M . Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005; 23(25):6207-19. DOI: 10.1200/JCO.2005.03.145. View

Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball D . A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer. 2004; 46(1):107-11. DOI: 10.1016/j.lungcan.2004.02.019. View

Xue J, Peng G, Yang J, Ding Q, Cheng J . Predictive factors of brain metastasis in patients with breast cancer. Med Oncol. 2013; 30(1):337. DOI: 10.1007/s12032-012-0337-2. View

10.

Chua D, Krzakowski M, Chouaid C, Pallotta M, Martinez J, Gottfried M . Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer. 2010; 11(3):176-81. DOI: 10.3816/CLC.2010.n.022. View

11.

Carew J, Nawrocki S, Kahue C, Zhang H, Yang C, Chung L . Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007; 110(1):313-22. PMC: 1896119. DOI: 10.1182/blood-2006-10-050260. View

12.

Harhaji-Trajkovic L, Arsikin K, Kravic-Stevovic T, Petricevic S, Tovilovic G, Pantovic A . Chloroquine-mediated lysosomal dysfunction enhances the anticancer effect of nutrient deprivation. Pharm Res. 2012; 29(8):2249-63. DOI: 10.1007/s11095-012-0753-1. View

13.

Reyes S, Herrera L, Ostrosky P, Sotelo J . Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery. 2001; 49(4):969-73. DOI: 10.1097/00006123-200110000-00033. View

14.

Bellodi C, Lidonnici M, Hamilton A, Helgason G, Soliera A, Ronchetti M . Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009; 119(5):1109-23. PMC: 2673867. DOI: 10.1172/JCI35660. View

15.

Briceno E, Calderon A, Sotelo J . Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol. 2007; 67(4):388-91. DOI: 10.1016/j.surneu.2006.08.080. View

16.

Briceno E, Reyes S, Sotelo J . Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus. 2005; 14(2):e3. DOI: 10.3171/foc.2003.14.2.4. View

17.

Savarino A, Boelaert J, Cassone A, Majori G, Cauda R . Effects of chloroquine on viral infections: an old drug against today's diseases?. Lancet Infect Dis. 2003; 3(11):722-7. PMC: 7128816. DOI: 10.1016/s1473-3099(03)00806-5. View

18.

Arrieta O, Villarreal-Garza C, Zamora J, Blake-Cerda M, de la Mata M, Zavala D . Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation. Radiat Oncol. 2011; 6:166. PMC: 3235073. DOI: 10.1186/1748-717X-6-166. View

19.

Verger E, Gil M, Yaya R, Vinolas N, Villa S, Pujol T . Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005; 61(1):185-91. DOI: 10.1016/j.ijrobp.2004.04.061. View

20.

Arrieta O, Nunez-Valencia C, Reynoso-Erazo L, Alvarado S, Flores-Estrada D, Angulo L . Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer. 2012; 77(1):205-11. DOI: 10.1016/j.lungcan.2012.02.005. View